To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT).
Methods
Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile.
Results
Mean age was 55.6 years (range 34-85). Mean time between PBT and DEX-I was 12.4 months (range 3-25). Mean follow-up was 9.9 months (range 4-15). Intravitreal Ozurdex® reduced exudative RD in 7 cases (70%) on average 3.1 months after injection with complete resolution of RD in 6 of these (60%). For half of the patients, their level of vision remained stable; the other half experienced a deterioration in visual acuity at the end of follow-up. No adverse effects were observed.
Conclusions
In this small case series, treatment with intravitreal DEX-I reduced exudative RD in the majority of cases and had an acceptable safety profile.
KiveläTEskelinSMäkitieTSummanenPExudative retinal detachment from malignant uveal melanoma: predictors and prognostic significance.Invest Ophthalmol Vis Sci. 2001;42(9):2085–2093.
3.
GragoudasELiWGoiteinMLaneAMMunzenriderJEEganKMEvidence-based estimates of outcome in patients irradiated for intraocular melanoma.Arch Ophthalmol. 2002;120(12):1665–1671.
4.
HamrouniZLevyCLumbrosoLet al.[Results of treating uveal melanoma with proton beam radiation: 10-year follow-up].J Fr Ophtalmol. 2005;28(8):833–839.
5.
EggerEZografosLSchalenbourgAet al.Eye retention after proton beam radiotherapy for uveal melanoma.Int J Radiat Oncol Biol Phys. 2003;55(4):867–880.
6.
EganKMGragoudasESSeddonJMet al.The risk of enucleation after proton beam irradiation of uveal melanoma.Ophthalmology. 1989;96(9):1377–1382discussion 1382-1383.
7.
FossAJWhelehanIHungerfordJLet al.Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma.Br J Ophthalmol. 1997;81(9):748–754.
8.
BoydSRTanDBunceCet al.Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.Br J Ophthalmol. 2002;86(4):448–452.
9.
GroenewaldCKonstantinidisLDamatoBEffects of radiotherapy on uveal melanomas and adjacent tissues.Eye (Lond). 2013;27(2):163–171.
10.
DamatoBProgress in the management of patients with uveal melanoma.The 2012 Ashton Lecture. Eye (Lond). 2012;26(9):1157–1172.
11.
RussoAAvitabileTUvaMet al.Radiation macular edema after Ru-106 plaque brachytherapy for choroidal melanoma resolved by an intravitreal implant.Case Rep Ophthalmol. 2012;3:71–76.
12.
BuiKMChowCCMielerWFTreatment of recalcitrant radiation maculopathy using intravitreal dexamethasone (Ozurdex) implant.Retin Cases Brief Rep. 2014;8(3):167–170.
13.
BaillifSMaschiCGastaudPCaujolleJPIntravitreal dexamethasone 0.7-mg implant for radiation macular edema after proton beam therapy for choroidal melanoma.Retina. 2013;33(9):1784–1790.
14.
TarmannLLangmannGMayerCWegerMHaasAWackernagelWOzurdex(®) reduces the retinal thickness in radiation maculopathy refractory to bevacizumab.Acta Ophthalmol. 2014;92(8):e694–e696.
15.
CaminalJMFlores-MorenoIAriasLet al.Intravitreal dexamethasone implant for radiation maculopathy secondary to plaque brachytherapy in choroidal melanoma.Retina. 2015;35(9):1890–1897.
16.
BazinLGambrelleJ[Combined treatment with photodynamic therapy and intravitreal dexamethasone implant (Ozurdex(®)) for circumscribed choroidal hemangioma].J Fr Ophtalmol. 2012;35(10):798–802Article in French.
17.
CebeciZOrayMTuncerSTugal TutkunIKirNIntravitreal dexamethasone implant (Ozurdex) and photodynamic therapy for vasoproliferative retinal tumours.Can J Ophthalmol. 2014;49(4):e83–e84.
18.
NewmanHFingerPTChinKJPavlickACSystemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma.Eur J Ophthalmol. 2011;21(6):796–801.
19.
MantelISchalenbourgABerginCPetrovicAWeberDCZografosLProphylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma.Am J Ophthalmol. 2014;158(4):693–701.e2.
20.
HoustonSKShahNVDecaturCet al.Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment.Clin Ophthalmol. 2013;7:193–198.
21.
DunavoelgyiRZehetmayerMSimaderCSchmidt-ErfurthURapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection.Clin Exp Ophthalmol. 2007;35(9):878–880.
22.
VásquezLMSomaniSAltomareFSimpsonERIntracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.Can J Ophthalmol. 2009;44(1):106–107.
23.
ParrozzaniRPilottoEDarioAMiglionicoGMidenaEIntravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.Am J Ophthalmol. 2013;155(1):127–133.e2.
24.
DesjardinsLLumbroso-Le RouicLLevy-GabrielCet al.Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients.Ophthalmic Res. 2006;38(5):255–260.
25.
CharDHBoveRPhillipsTLLaser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments.Am J Ophthalmol. 2003;136(1):180–182.
26.
GibranSKKapoorKGManagement of exudative retinal detachment in choroidal melanoma.Clin Exp Ophthalmol. 2009;37(7):654–659.
27.
CassouxNCayetteSPlancherCet al.Choroidal melanoma: does endoresection prevent neovascular glaucoma in patient treated with proton beam irradiation?Retina. 2013;33(7):1441–1447.
28.
BechrakisNEHöchtSMartusPKreuselKMHeeseJFoersterMH[Endoresection following proton beam irradiation of large uveal melanomas].Ophthalmologe. 2004;101(4):370–376.
29.
KonstantinidisLGroenewaldCCouplandSEDamatoBTrans-scleral local resection of toxic choroidal melanoma after proton beam radiotherapy.Br J Ophthalmol. 2014;98(6):775–779.
30.
Garcia-ArumiJLeilaMZapataMAet al.Endoresection technique with/without brachytherapy for management of high posterior choroidal melanoma: extended follow-up results.Retina. 2015;35(4):628–637.
31.
LeopoldIHNonsteroidal and steroidal anti-inflammatory agents.In: Sears ML, Tarkkanen A, eds. Surgical Pharmacology of the EyeNew York:Raven Press; 1985:83-133.
